Methotrexate and its mechanisms of action in inflammatory arthritis

[1]  M. Zeidler,et al.  JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy , 2019, Journal of leukocyte biology.

[2]  A. Barton,et al.  Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[3]  N. Wulffraat,et al.  Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis , 2018, PloS one.

[4]  P. Dieudé,et al.  Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications , 2018, Annals of the rheumatic diseases.

[5]  A. Barton,et al.  Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) , 2018, Arthritis Research & Therapy.

[6]  P. Dönnes,et al.  Methotrexate and BAFF interaction prevents immunization against TNF inhibitors , 2018, Annals of the rheumatic diseases.

[7]  M. Weinblatt.  Methotrexate: who would have predicted its importance in rheumatoid arthritis? , 2018, Arthritis Research & Therapy.

[8]  Borbala Mifsud,et al.  Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients , 2018, The Pharmacogenomics Journal.

[9]  C. Malemud,et al.  The role of the JAK/STAT signal pathway in rheumatoid arthritis , 2018, Therapeutic advances in musculoskeletal disease.

[10]  J. Jacobs,et al.  Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors , 2018, Annals of the rheumatic diseases.

[11]  Cristina Municio,et al.  Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism , 2018, Annals of the rheumatic diseases.

[12]  D. Allard,et al.  Targeting A2 adenosine receptors in cancer , 2017, Immunology and cell biology.

[13]  E. Smolewska,et al.  In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine? , 2017, Current Rheumatology Reports.

[14]  M. Schiff,et al.  Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis , 2017, Rheumatology International.

[15]  Juan Shi,et al.  p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis , 2016, Arthritis Research & Therapy.

[16]  Sam W. Lee,et al.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation , 2016, Nature Reviews Immunology.

[17]  C. Martínez-A,et al.  p21 mediates macrophage reprogramming through regulation of p50-p50 NF-κB and IFN-β. , 2016, The Journal of clinical investigation.

[18]  A. Dopazo,et al.  Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis , 2016, Annals of the rheumatic diseases.

[19]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[20]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[21]  T. Kojima,et al.  Concomitant Methotrexate Protects Against Total Knee Arthroplasty in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors , 2015, The Journal of Rheumatology.

[22]  A. Kaneko,et al.  Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan , 2015, Arthritis care & research.

[23]  Qikai Xu,et al.  The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4 , 2015, Science.

[24]  Stephen Brown,et al.  Methotrexate Is a JAK/STAT Pathway Inhibitor , 2015, PloS one.

[25]  F. Liew,et al.  Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis , 2015, Proceedings of the National Academy of Sciences.

[26]  N. Olsen,et al.  Methotrexate Inhibits NF‐κB Activity Via Long Intergenic (Noncoding) RNA–p21 Induction , 2014, Arthritis & rheumatology.

[27]  P. Dinarvand,et al.  Adenosine Regulates the Proinflammatory Signaling Function of Thrombin in Endothelial Cells , 2014, Journal of cellular physiology.

[28]  C. Harris,et al.  Caught in the cross fire: p53 in inflammation. , 2014, Carcinogenesis.

[29]  B. Fredholm,et al.  Adenosine increases LPS‐induced nuclear factor kappa B activation in smooth muscle cells via an intracellular mechanism and modulates it via actions on adenosine receptors , 2014, Acta physiologica.

[30]  N. Olsen,et al.  Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937 , 2014, Arthritis Research & Therapy.

[31]  Fan Yang,et al.  Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. , 2014, Molecular cell.

[32]  Kotaro Suzuki,et al.  Tumor Suppressor p53 Inhibits Systemic Autoimmune Diseases by Inducing Regulatory T Cells , 2013, The Journal of Immunology.

[33]  Y. Konttinen,et al.  Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. , 2013, Seminars in arthritis and rheumatism.

[34]  B. Shea.  Folic acid or folinic acid for reducing side effects of methotrexate for people with rheumatoid arthritis , 2013, Journal of evidence-based medicine.

[35]  B. Cronstein,et al.  Activation of adenosine A2A receptor reduces osteoclast formation via PKA‐ and ERK1/2‐mediated suppression of NFκB nuclear translocation , 2013, British journal of pharmacology.

[36]  Vassilis G Gorgoulis,et al.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. , 2013, Cancer cell.

[37]  D. Menendez,et al.  Interactions between the tumor suppressor p53 and immune responses , 2013, Current opinion in oncology.

[38]  Kotb Abdelmohsen,et al.  LincRNA-p21 suppresses target mRNA translation. , 2012, Molecular cell.

[39]  Howard Y. Chang,et al.  Genome regulation by long noncoding RNAs. , 2012, Annual review of biochemistry.

[40]  N. Olsen,et al.  Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. , 2012, Arthritis and rheumatism.

[41]  N. Olsen,et al.  Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. , 2011, Arthritis and rheumatism.

[42]  A. Barton,et al.  A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register , 2010, The Pharmacogenomics Journal.

[43]  S. Luban,et al.  Citrullinated peptide and its relevance to rheumatoid arthritis: an update , 2010, International journal of rheumatic diseases.

[44]  J. Rinn,et al.  A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response , 2010, Cell.

[45]  J. Qian,et al.  Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of small-for-size liver transplantation. , 2010, Transplantation proceedings.

[46]  E. Mazzon,et al.  GW0742, A HIGH-AFFINITY PPAR -&bgr;/&dgr; AGONIST, INHIBITS ACUTE LUNG INJURY IN MICE , 2010, Shock.

[47]  B. Cronstein,et al.  Methotrexate—how does it really work? , 2010, Nature Reviews Rheumatology.

[48]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[49]  F. Pedata,et al.  ADENOSINE A2A RECEPTOR-SELECTIVE STIMULATION REDUCES SIGNALING PATHWAYS INVOLVED IN THE DEVELOPMENT OF INTESTINE ISCHEMIA AND REPERFUSION INJURY , 2009, Shock.

[50]  A. Hale,et al.  Critical Role for Tetrahydrobiopterin Recycling by Dihydrofolate Reductase in Regulation of Endothelial Nitric-oxide Synthase Coupling , 2009, The Journal of Biological Chemistry.

[51]  B. Levy,et al.  Tetrahydrobiopterin Recycling, a Key Determinant of Endothelial Nitric-oxide Synthase-dependent Signaling Pathways in Cultured Vascular Endothelial Cells* , 2009, Journal of Biological Chemistry.

[52]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[53]  B. Cronstein,et al.  Adenosine A2A Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling Pathway , 2007, Molecular Pharmacology.

[54]  Georg Schett,et al.  Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.

[55]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. , 2007, Arthritis and rheumatism.

[56]  S. Leibovich,et al.  Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. , 2006, Molecular biology of the cell.

[57]  S. Friedman,et al.  Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis , 2006, British journal of pharmacology.

[58]  L. Chibnik,et al.  Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[59]  A. Zernecke,et al.  CD73/Ecto-5′-Nucleotidase Protects Against Vascular Inflammation and Neointima Formation , 2006, Circulation.

[60]  B. Cronstein,et al.  Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis , 2006, Arthritis research & therapy.

[61]  R. Tibbetts,et al.  Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic Stimuli , 2006, Science.

[62]  P. van Riel,et al.  Methotrexate modulates the kinetics of adenosine in humans in vivo , 2005, Annals of the rheumatic diseases.

[63]  H. Cai,et al.  Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Pu Wang,et al.  Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. , 2005, Diabetes.

[65]  T. Palmer,et al.  Specific Inhibition of Nuclear Factor-κB–Dependent Inflammatory Responses by Cell Type-Specific Mechanisms upon A2A Adenosine Receptor Gene Transfer , 2004, Molecular Pharmacology.

[66]  A. Ohta,et al.  Cutting Edge: Physiologic Attenuation of Proinflammatory Transcription by the Gs Protein-Coupled A2A Adenosine Receptor In Vivo , 2004, The Journal of Immunology.

[67]  G. Nesher,et al.  Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[68]  Y. Okuda,et al.  Regulatory role of p53 in experimental autoimmune encephalomyelitis , 2003, Journal of Neuroimmunology.

[69]  H. Wong,et al.  The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP‐1 cells , 2002, Journal of leukocyte biology.

[70]  P. Matzinger,et al.  Danger signals: SOS to the immune system. , 2001, Current opinion in immunology.

[71]  B. Cronstein,et al.  Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. , 2000, Arthritis and rheumatism.

[72]  G. Alarcón,et al.  Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. , 1998, The Journal of rheumatology.

[73]  B. Cronstein,et al.  Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate‐induced nodulosis in rheumatoid arthritis , 1997 .

[74]  G. Alarcón,et al.  Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: comment on the guidelines for monitoring drug therapy. , 1997, Arthritis and rheumatism.

[75]  A. Oksenberg,et al.  Temporal variations of adenosine metabolism in human blood. , 1996, Chronobiology international.

[76]  T. Moore,et al.  In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. , 1996, Clinical and experimental rheumatology.

[77]  V. C. Sánchez.  Circadian variations of adenosine and of its metabolism. Could adenosine be a molecular oscillator for circadian rhythms , 1995 .

[78]  G. Alarcón,et al.  Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[79]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[80]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[81]  T. Ochi,et al.  Levels of urinary polyamines in patients with rheumatoid arthritis. , 1993, The Journal of rheumatology.

[82]  J. Esdaile,et al.  Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. , 1993, Arthritis and rheumatism.

[83]  S. Vidrio,et al.  Day-night variations of adenosine and its metabolizing enzymes in the brain cortex of the rat — possible physiological significance for the energetic homeostasis and the sleep-wake cycle , 1993, Brain Research.

[84]  G. Alarcón,et al.  Folate supplementation and methotrexate. , 1993, Annals of the rheumatic diseases.

[85]  T. Ochi,et al.  Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. , 1992, The Journal of rheumatology.

[86]  D. M. Hoffman,et al.  Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. , 1991, Annals of the rheumatic diseases.

[87]  T. Moore,et al.  In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. , 1991, Annals of the rheumatic diseases.

[88]  T. Moore,et al.  The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. , 1990, Arthritis and rheumatism.

[89]  D. Furst,et al.  Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. , 1989, Journal of pharmaceutical sciences.

[90]  M. Yaron,et al.  The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. , 1988, Arthritis and rheumatism.

[91]  J. Kremer,et al.  Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. , 1986, Arthritis and rheumatism.

[92]  J. Kremer,et al.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[93]  G. Curt,et al.  Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.

[94]  C. Allegra,et al.  Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[96]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[97]  W. Stolzmann,et al.  Studies on in vitro lymphocyte proliferation in cultures synchronized by the inhibition of DNA synthesis. I. Variability of S plus G2 periods of first generation cells. , 1969, Experimental cell research.

[98]  R. Gubner,et al.  THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITY: II. Effect of Aminopterin in Rheumatoid Arthritis and Psoriasis , 1951, The American journal of the medical sciences.

[99]  M. Sitkovsky,et al.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases , 2017, Nature Reviews Rheumatology.

[100]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[101]  Guillermo I Carrillo,et al.  A Controlled Clinical Trial , 2015 .

[102]  N. Olsen,et al.  Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes. , 2015, Rheumatology.

[103]  Kotaro Suzuki,et al.  Role of p53 in systemic autoimmune diseases. , 2014, Critical reviews in immunology.

[104]  M. Weinblatt.  Methotrexate in rheumatoid arthritis: a quarter century of development. , 2013, Transactions of the American Clinical and Climatological Association.

[105]  Zoltán Szabó,et al.  Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. , 2010, Autoimmunity reviews.

[106]  Polly Matzinger,et al.  Friendly and dangerous signals: is the tissue in control? , 2007, Nature Immunology.

[107]  B. Cronstein,et al.  Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. , 2003, Arthritis and rheumatism.

[108]  V. Chagoya de Sánchez.  Circadian variations of adenosine and of its metabolism. Could adenosine be a molecular oscillator for circadian rhythms? , 1995, Canadian journal of physiology and pharmacology.

[109]  G. Alarcón,et al.  The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[110]  K. Johnson.  An Update. , 1984, Journal of food protection.